![](https://tracker.live.rns-distribution.com/track.live-rns/5022969_75d1671758db0ed18eba2dbba83793b2.png)
(LSE: PEYS/PEY)
Princess Private Equity Holding Limited
Princess publishes November NAV
· Net asset value decreased by 0.9% to EUR 14.47 per share, net of the interim dividend of EUR 0.365 per share; total NAV at EUR 1 billion
· The FY 2023 dividend of EUR 0.73 per share, which includes the first interim dividend paid in June, aligns with the objective to distribute 5% of opening NAV annually
· Value creation contributed to NAV (+0.7%), however the gains were outweighed by adverse currency movements (-1.3%), caused by the strengthening of the euro against the US dollar
· Agreed sale of Civica
At portfolio level, PCI Pharma Services ("PCI"), DiversiTech and Pharmathen, all three companies amongst the top 20 positions, were notable contributors to value creation during the month. The value of PCI, a global provider of outsourced pharmaceutical services based in the US, increased on the back of its continued robust financial performance driven by continued organic growth across all segments including its injectable business, Lyophilization Services of New England.
DiversiTech, a manufacturer of components and supplies for the US residential heating, ventilation, and air conditioning ("HVAC") market, experienced an increase in value driven by a healthy combination of both organic and inorganic growth, which was further supported by the earlier acquisition of Castel Engineering (November 2022) and Pro1 Themostats (June 2023). Moreover, DiversiTech acquired GIA Group, an Italian manufacturer and supplier of HVAC parts. The acquisition will greatly expand the product range and services of DiversiTech International, a new subsidiary business formed after DiversiTech's acquisition of Castel Engineering.
Pharmathen, a leading developer of advanced drug delivery technologies for complex pharmaceutical products, appreciated in value during the month, reflecting its continued strong financial performance driven by higher-than-expected sales and strong growth in long-acting injectable products in the US and European market. The acquisition of a Greek developer and manufacturer of peptide active pharmaceutical ingredients offers valuable vertical integration and enhances the company's development capabilities, contributing to a positive outlook for future growth.
Finally, Partners Group, acting on behalf of its clients, has agreed to sell Civica, a global provider of cloud software solutions for the public sector. Partners Group acquired Civica in 2017 and has since transformed Civica into a pure software business, pivoting away from its previous services such as IT management. This has driven Civica's strong growth, with EBITDA doubling since Partners Group's investment. During Partners Group's ownership, Civica has accelerated organic topline growth, developed a cloud offering, built out its offshore R&D operations, and executed 24 highly complementary add-on acquisitions. The sale is expected to complete in Q2 2024.
Further information is available in the monthly report, which can be accessed via: http://www.princess-privateequity.net/en/investor-relations/financial-reports/.
Ends.
About Princess
Princess is an investment holding company founded in 1999 and domiciled in Guernsey. It invests in private equity direct investments. Princess is managed in its investment activities by Partners Group, a global private markets investment management firm with USD 142 billion in investment programs under management in private markets, of which USD 74 billion in private equity. Princess aims to provide shareholders with long-term capital growth and an attractive dividend yield. Princess is traded on the Main Market of the London Stock Exchange (ticker: PEY for the Euro Quote; PEYS for the Sterling Quote).
Contacts
Princess Private Equity Holding Limited:
princess@partnersgroup.com
www.princess-privateequity.net
Investor relations contact: Sarah Page Phone: +44 20 7575 2695 E-mail: sarah.page@partnersgroup.com | Media relations contact: Jenny Blinch Phone: +41 41 784 65 26 E-mail: jenny.blinch@partnersgroup.com |
Registered Number: 35241 LEI: 54930038LU8RDPFFVJ57
Notes:
1. Note that references in this announcement to Princess Private Equity Holding Limited have been abbreviated to "Princess" or "Company". References to Partners Group AG have been abbreviated to "Partners Group " or "Investment Manager".
2. This document does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for any securities and neither is it intended to be an investment advertisement or sales instrument of Princess Private Equity Holdings. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes must inform themselves about and observe any such restrictions on the distribution of this document. In particular, this document and the information contained therein is not for distribution or publication, neither directly nor indirectly, in or into the United States of America, Canada, Australia or Japan.
3. This document may have been prepared using financial information contained in the books and records of the product described herein as of the reporting date. This information is believed to be accurate but has not been audited by any third party. This document may describe past performance, which may not be indicative of future results. No liability is accepted for any actions taken on the basis of the information provided in this document. Neither the contents of Princess' website nor the contents of any website accessible from hyperlinks on Princess' website (or any other website) is incorporated into, or forms part of, this announcement.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.